Literature DB >> 24415647

Culture-inappropriate antibiotic therapy decreases quality of life improvement after sinus surgery.

Zi Zhang1, James N Palmer, Knashawn H Morales, Timothy J Howland, Laurel J Doghramji, Nithin D Adappa, Alexander G Chiu, Noam A Cohen, Ebbing Lautenbach.   

Abstract

BACKGROUND: Despite their widespread use, antibiotics have not been shown to improve chronic rhinosinusitis (CRS) outcomes. We aimed to determine whether culture-inappropriate postoperative antibiotic therapy was associated with less quality-of-life (QOL) improvement following functional endoscopic sinus surgery (FESS).
METHODS: This retrospective cohort study recruited 376 adult CRS patients undergoing FESS between October 1, 2007 to December 31, 2011. Patient demographics, comorbidities and medications were collected at baseline. Trimethoprim-sulfamethoxazole and clindamycin were administered for 2 weeks postoperatively. The antibiotic appropriateness was determined based on bacterial resistance profile of organisms identified during intraoperative culture. The QOL outcome was defined as change of 22-item Sinonasal Outcome Test scores from preoperative visit to 1-month, 3-month, and 6-month post-FESS. Clinically significant difference was defined as at least 0.5 standard deviations (SD) of baseline QOL score in the reference group. Mixed-effects regression models were performed.
RESULTS: Seven percent of patients (n = 27) had culture-inappropriate antibiotic therapy, and additional 5% (n = 19) had culture-specific antibiotic adjustment. Compared to patients with culture-appropriate antibiotics, patients with culture-inappropriate antibiotics had significantly less improvement of QOL from baseline to postoperative 1-month and 3-month follow-up where the difference became clinically significant; patients with antibiotic adjustment had more QOL improvement from baseline to 1-month follow-up, but their QOL worsened at 3-month follow-up, and these changes were not clinically significant. However, all effects washed out at 6-month follow-up with no significant differences.
CONCLUSION: Culture-inappropriate postoperative antibiotic therapy decreased short-term QOL improvement to a clinically meaningful level after FESS. Culture guided selection of antibiotics may improve short-term FESS outcome.
© 2014 ARS-AAOA, LLC.

Entities:  

Keywords:  22-item Sinonasal Outcome Test; SNOT-22; antibiotic therapy; chronic rhinosinusitis; culture; endoscopic sinus surgery; quality of life

Mesh:

Substances:

Year:  2014        PMID: 24415647      PMCID: PMC4004654          DOI: 10.1002/alr.21277

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  38 in total

1.  EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists.

Authors:  Wytske Fokkens; Valerie Lund; Joaquim Mullol
Journal:  Rhinology       Date:  2007-06       Impact factor: 3.681

2.  Clinical factors associated with bacterial biofilm formation in chronic rhinosinusitis.

Authors:  Zi Zhang; Jennifer M Kofonow; Brian S Finkelman; Laurel Doghramji; Alexander G Chiu; David W Kennedy; Noam A Cohen; James N Palmer
Journal:  Otolaryngol Head Neck Surg       Date:  2011-02-03       Impact factor: 3.497

3.  Correlation between preoperative symptom scores, quality-of-life questionnaires, and staging with computed tomography in patients with chronic rhinosinusitis.

Authors:  David A M Wabnitz; Salil Nair; P J Wormald
Journal:  Am J Rhinol       Date:  2005 Jan-Feb

4.  Clinical and symptom criteria for the accurate diagnosis of chronic rhinosinusitis.

Authors:  Neil Bhattacharyya
Journal:  Laryngoscope       Date:  2006-07       Impact factor: 3.325

5.  Direct nasopharyngeal reflux of gastric acid is a contributing factor in refractory chronic rhinosinusitis.

Authors:  John M DelGaudio
Journal:  Laryngoscope       Date:  2005-06       Impact factor: 3.325

6.  Clinical practice guideline: adult sinusitis.

Authors:  Richard M Rosenfeld; David Andes; Neil Bhattacharyya; Dickson Cheung; Steven Eisenberg; Theodore G Ganiats; Andrea Gelzer; Daniel Hamilos; Richard C Haydon; Patricia A Hudgins; Stacie Jones; Helene J Krouse; Lawrence H Lee; Martin C Mahoney; Bradley F Marple; Col John P Mitchell; Robert Nathan; Richard N Shiffman; Timothy L Smith; David L Witsell
Journal:  Otolaryngol Head Neck Surg       Date:  2007-09       Impact factor: 3.497

7.  Impact of aspirin intolerance on outcomes of sinus surgery.

Authors:  Jamie L Robinson; Susan Griest; Kenneth E James; Timothy L Smith
Journal:  Laryngoscope       Date:  2007-05       Impact factor: 3.325

8.  Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia.

Authors:  L J Newman; T A Platts-Mills; C D Phillips; K C Hazen; C W Gross
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis.

Authors:  Ben Wallwork; William Coman; Alan Mackay-Sim; Lennart Greiff; Anders Cervin
Journal:  Laryngoscope       Date:  2006-02       Impact factor: 3.325

10.  The role of allergy and smoking in chronic rhinosinusitis and polyposis.

Authors:  Steven M Houser; Kevin J Keen
Journal:  Laryngoscope       Date:  2008-09       Impact factor: 3.325

View more
  3 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Are multiple sinus cultures necessary during sinus surgery for chronic rhinosinusitis?

Authors:  Craig Miller; Greg E Davis
Journal:  Int Forum Allergy Rhinol       Date:  2018-01-05       Impact factor: 3.858

Review 3.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.